Contrasting roles of Leu356 in the human CCK1 receptor for antagonist SR 27897 and agonist SR 146131 binding

被引:15
作者
Gouldson, P [1 ]
Legoux, P [1 ]
Carillon, C [1 ]
Delpech, B [1 ]
Le Fur, G [1 ]
Ferrara, P [1 ]
Shire, D [1 ]
机构
[1] Sanofi Synthelabo, Ctr Labege, F-31676 Labege, France
关键词
cholecystokinin receptor; mutagenesis; chimeric receptor; transmembrane domain seven; SR; 27597; 146131; CCK-8S;
D O I
10.1016/S0014-2999(99)00612-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A new highly specific, potent non-peptide agonist for the cholecystokinin subtype 1 receptor (CCK1), SR 146131 (2-[4-(4-chloro-2,5-dimethoxyphenyl)-5- (2-cyclohexyl-ethyl)-thiazol-2-ylcarbamoyl]-5,7-dimethyl-indol-1-yl-1-acetic acid) was recently described [Bignon, E., Bachy, A., Boigegrain, R., Brodin, R., Cottineau, M., Gully, D., Herbert, J.-M., Keane, P., Labie, C., Molimard, J.-C., Olliero, D., Oury-Donat, F., Petereau, C., Prabonneaud, V., Rockstroh, M.-P., Schaeffer, P., Servant, O. Thurneyssen, O., Soubrie, P., Pascal, M., Maffrand, J.-P., Le Fur, G., 1999. SR 146131: a new, potent, orally active and selective non-peptide cholecystokinin subtype I receptor agonist: I. In vitro studies. J. Pharmacol. Exp. Ther. 289, 742-751]. From binding and activity assays with chimeric constructs of human CCK1 and the cholecystokinin subtype 2 receptor (CCK2) and receptors carrying point mutations, we show that Leu(356), situated in transmembrane domain seven in the CCK1 receptor, is a putative contact point for SR 146131. In contrast, Leu(356) is probably not in contact with the CCK1 receptor specific antagonist SR 27897 (1-[2-(4-(2-chlorophenyl)thiazol-2-yl)aminocarbonyl indoyl]acetic acid), a compound structurally related to SR 146131, since its replacement by alanine, histidine or asparagine gave receptors having wild-type CCK1 receptor SR 27897 binding affinity. Previous mutational analysis of His(381), the cognate position in the rat CCK2 receptor, had implicated it as being involved in subtype specificity for SR 27897, results which we confirm with corresponding mutations in the human CCK2 receptor. Moreover, binding and activity assays with the natural CCK receptor agonist, CCK-8S, show that CCK-8S is more susceptible to the mutations in that position in the CCK1 receptor than in the CCK2 receptor. The results suggest different binding modes for SR 27897, SR 146131 and CCK-8S in each CCK receptor subtype. O 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:339 / 346
页数:8
相关论文
共 31 条
[1]   A SINGLE-POINT MUTATION INCREASES THE AFFINITY OF SEROTONIN 5-HT1D-ALPHA, 5-HT1D-BETA, 5-HT1E AND 5-HT1F RECEPTORS FOR BETA-ADRENERGIC ANTAGONISTS [J].
ADHAM, N ;
TAMM, JA ;
SALON, JA ;
VAYSSE, PJJ ;
WEINSHANK, RL ;
BRANCHEK, TA .
NEUROPHARMACOLOGY, 1994, 33 (3-4) :387-391
[2]  
Bignon E, 1999, J PHARMACOL EXP THER, V289, P742
[3]   MOLECULAR-CLONING, FUNCTIONAL EXPRESSION AND CHROMOSOMAL LOCALIZATION OF THE HUMAN CHOLECYSTOKININ TYPE-A RECEPTOR [J].
DEWEERTH, A ;
PISEGNA, JR ;
HUPPI, K ;
WANK, SA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 194 (02) :811-818
[4]  
FONG TM, 1992, J BIOL CHEM, V267, P25664
[5]   THE EXTRACELLULAR DOMAIN OF THE NEUROKININ-1 RECEPTOR IS REQUIRED FOR HIGH-AFFINITY BINDING OF PEPTIDES [J].
FONG, TM ;
YU, H ;
HUANG, RRC ;
STRADER, CD .
BIOCHEMISTRY, 1992, 31 (47) :11806-11811
[6]   Met-195 of the cholecystokinin-A receptor interacts with the sulfated tyrosine of cholecystokinin and is crucial for receptor transition to high affinity state [J].
Gigoux, V ;
Escrieut, C ;
Silvente-Poirot, S ;
Maigret, B ;
Gouilleux, L ;
Fehrentz, JA ;
Gully, D ;
Moroder, L ;
Vaysse, N ;
Fourmy, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) :14380-14386
[7]   PERIPHERAL BIOLOGICAL-ACTIVITY OF SR-27897 - A NEW POTENT NONPEPTIDE ANTAGONIST OF CCK(A) RECEPTORS [J].
GULLY, D ;
FREHEL, D ;
MARCY, C ;
SPINAZZE, A ;
LESPY, L ;
NELIAT, G ;
MAFFRAND, JP ;
LEFUR, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 232 (01) :13-19
[8]   Direct identification of a second distinct site of contact between cholecystokinin and its receptor [J].
Hadac, EM ;
Pinon, DI ;
Ji, ZS ;
Holicky, EL ;
Henne, RM ;
Lybrand, TP ;
Miller, LJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (21) :12988-12993
[9]   ENGINEERING HYBRID GENES WITHOUT THE USE OF RESTRICTION ENZYMES - GENE-SPLICING BY OVERLAP EXTENSION [J].
HORTON, RM ;
HUNT, HD ;
HO, SN ;
PULLEN, JK ;
PEASE, LR .
GENE, 1989, 77 (01) :61-68
[10]   IDENTIFICATION OF RESIDUES INVOLVED IN LIGAND-BINDING TO THE NEUROKININ-2 RECEPTOR [J].
HUANG, RRC ;
VICARIO, PP ;
STRADER, CD ;
FONG, TM .
BIOCHEMISTRY, 1995, 34 (31) :10048-10055